163 related articles for article (PubMed ID: 9074718)
1. [Dysmegakaryocytopoiesis and dysthrombopoiesis in myeloproliferative syndromes].
Brière J; Kiladjian JJ; Peynaud-Debayle E
C R Seances Soc Biol Fil; 1996; 190(5-6):533-9. PubMed ID: 9074718
[TBL] [Abstract][Full Text] [Related]
2. Megakaryocytes and platelets in myeloproliferative disorders.
Briere J; Kiladjian JJ; Peynaud-Debayle E
Baillieres Clin Haematol; 1997 Feb; 10(1):65-88. PubMed ID: 9154316
[TBL] [Abstract][Full Text] [Related]
3. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Michiels JJ; Juvonen E
Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
[TBL] [Abstract][Full Text] [Related]
4. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
Wehmeier A; Südhoff T; Meierkord F
Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
6. [Megakaryocytopoiesis in myeloproliferative disorders].
Podolak-Dawidziak M
Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
[No Abstract] [Full Text] [Related]
7. Clonality assays and megakaryocyte culture techniques in essential thrombocythemia.
Yan L; Elkassar N; Gardin C; Briere J
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():31-40. PubMed ID: 8951770
[TBL] [Abstract][Full Text] [Related]
8. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
9. [Emperipolesis in megakaryocytes in patients with thrombocytosis in the course of myeloproliferative disorders].
Bobik R; Podolak-Dawidziak M; Kiełbiński M; Jeleń M; Wróbel T
Acta Haematol Pol; 1995; 26(2):179-83. PubMed ID: 7653223
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
11. The chronic myeloproliferative disorders: clonality and clinical heterogeneity.
Spivak JL
Semin Hematol; 2004 Apr; 41(2 Suppl 3):1-5. PubMed ID: 15190515
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders.
Kralovics R; Skoda RC
Blood Rev; 2005 Jan; 19(1):1-13. PubMed ID: 15572213
[TBL] [Abstract][Full Text] [Related]
13. Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles.
Petrides PE; Siegel F
Blood Cells Mol Dis; 2006; 36(3):379-84. PubMed ID: 16563815
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin: biology and clinical potentials.
Miyazaki H; Kato T
Int J Hematol; 1999 Dec; 70(4):216-25. PubMed ID: 10643146
[TBL] [Abstract][Full Text] [Related]
15. Megakaryopoiesis in chronic myeloproliferative diseases. A morphometric evaluation with special emphasis on primary thrombocythemia.
Thiele J; Funke S; Holgado S; Choritz H; Georgii A
Anal Quant Cytol; 1984 Sep; 6(3):155-67. PubMed ID: 6594964
[TBL] [Abstract][Full Text] [Related]
16. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
17. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders.
Douglas VK; Tallman MS; Cripe LD; Peterson LC
Am J Clin Pathol; 2002 Jun; 117(6):844-50. PubMed ID: 12047134
[TBL] [Abstract][Full Text] [Related]
19. Early down-regulation of Bcl-xL expression during megakaryocytic differentiation of thrombopoietin-induced CD34+ bone marrow cells in essential thrombocythemia.
Zhang L; Zhao H; Sun A; Lu S; Liu B; Tang F; Feng Y; Zhao L; Yang R; Han ZC
Haematologica; 2004 Oct; 89(10):1199-206. PubMed ID: 15477204
[TBL] [Abstract][Full Text] [Related]
20. Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders.
Li Y; Hetet G; Kiladjian JJ; Gardin C; Grandchamp B; Briere J
Br J Haematol; 1996 Jan; 92(1):60-6. PubMed ID: 8562412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
